4 курс / Акушерство и гинекология / Журавлева_Е_В_Патогенетическая_профилактика_повторных_преэклампсий

[158]Nørgård B, Puhó E, Czeizel AE et al. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study // Am J Obstet Gynecol. 2005 Mar;192(3):922-3.

[159]Palomo IG, Segovia FM, Alarcon ML et al. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome // Front Biosci. 2007 May 1;12:3093-103.(177)

[160]Pandey M, Mantel GD, Moodley J. Audit of severe acute morbidity in hypertensive pregnancies in a developing country. J Obstet Gynecol 2004; 24:387391

[161] зPieroniDM, MorelliF,LourenVM et al. Cytokine gene variants and

venous thrombotic risk in the BRATROS (BRAZILIAN THROMBOSIS STUDY) // Thromb Res. 2007;120(2):221-9.

[162]Quenby S, Mountfield S, Cartwright JE et al. Effects of low-molecular- weight and unfractionated heparin on trophoblast function // Obstet Gynecol. 2004 Aug;104(2):354-61.

[163]Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) // BMJ. 1997 Jan25;314(7076):253-7.

[164]Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010; 19(4): 460-9

[165]RCOG 2010 Management of severe preeclampsia and eclampsia. Guideline No 10(A) March 2006 Reviewed 2010

[166]Redman CW, Sargent IL. Preeclampsia, the placenta and the maternal systematic inflammatory response- a review. Placenta 2003; 24 (Suppl 1): 921-27

151

[167]Redman CW, Sargent IL. Preeclampsia, the placenta and the maternal systematic inflammatory response- a review. Placenta 2003; 24 (Suppl 1): 921-27

[168]Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. American Journal of Obstetrics and Gynecology.2000;183:S1-S22

[169]Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183:s1-22

[170]Rey E, Garnean P et al. Dalteparin for the prevention of recurrence of placenta-medicated complications of pregnancy in women without thrombophilia: a pilot randomized coutrolled trial. J. Thromb.Haemost. 2009; 7(1): 58-64

[171]Richter C, Sitzmann J, Lang P et al. Excretion of low molecular weight heparin in human milk // Br J Clin Pharmacol. 2001 Dec;52(6):708-10

[172]Riyazi N, Leeda M et al. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur. J. Obste.Gynecol.Reprod. Biol. 1998; 80 (1): 49-54

[173]Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low molecular weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth retriction: a preliminary study // Eur J Obstet Gynecol Reprod Biol. 1998;80: 49-54.

[174]Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy: a systematic review. Br. J. Haematol .2005; 132: 171-96

[175]Rodger MA, Betancourt MT, Clark P et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies // PLoS Med. 2010 Jun 15;7(6):e1000292

152

[176]Rodger MA, Carrier M, Keely E, et al. The management of thrombophilia during pregnancy: a Canadian survey // J Obstet Gynaecol Can. 2002; 24:946-952.

[177]Rosendaal F.R. et al. Estrogens, Progesterons and Thrombosis. J. Thromb.Hemost. 2003; 1: 1371-80

[178]Rosendaal F.R. et al. Estrogens, Progesterons and Thrombosis. J. Thromb.Hemost. 2003; 1: 1371-80

[179]Saftlas AF, Olson DR, Atrash HK, et al. National trends in the incidence of abruptio placentae, 1979–1987 // Obstet Gynecol 1991;78:1081–6.

[180]Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation // J Reprod Immunol. 2008 Jan;77(1):51-6. (199)

[181]Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women // Thromb Haemost. 1996;75: 387-388.

[182]Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review // Thromb Haemost. 1999 May;81(5):668-72.

[183]Sarig G, Lanir N, Hoffman R, Brenner B. Protein C global assay in the evaluation of women with idiopathic pregnancy loss // Thromb.Haemost.2002;88: 32-36.

[184]Saving Mothers. Third Report on Confidential Enquiries into Maternal Deaths in South Africa 2002-2004. Department of Health, Pretoria, Pretoria

[185]Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabetic Med 2005; 22:674-82

[186]Schlafke S, Enders AC. Cellular basis of interaction between throphoblast and uterus at implantation. Biol Reprod 1975; 12: 41-65

153

[187]Sheiner E, Shoham-Vardi I, Hadar A, Hallak M, Hackmon R, Mazor M. Incidence, obstetric risk factors and pregnancy outcome of preterm placental abruption: a retrospective analysis // J Matern Fetal Neonatal Med 2002;11:34

[188]Sibai B, Dekker G, Cupfermink M. Preeclampsia. Lancet 2005; 365(9461): 785-799

[189]Soleymanlon N et al. Molecular evidence of placental hypoxia in preeclampsia. J. Clin.Endocrinol.Metab. 2005; 90 (7): 4299-4308

[190]Sood R, Kalloway S, Mast AE et al. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells // Blood. 2006 Apr 15;107(8):3173-80. (213)

[191]Soriano D, Carp H, Seidman DS et al. Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events // Acta Obstet Gynecol Scand. 2002 Mar;81(3):104.

[192]Soriano D, Carp H, Seidman DS et al. Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events // Acta Obstet Gynecol Scand. 2002 Mar;81(3):204-7.

[193]Steegers-Theunissen RP, Van Iersel CA, Peer PG et al. Hyperhomocysteinemia, pregnancy complications, and the timing of investigation // Obstet Gynecol. 2004 Aug;104(2):336-43

[194]Sugiura M. Pregnancy and delivery in protein C-deficiency // Curr Drug Targets. 2005 Aug;6(5):577-83.

[195]Tang CH, Wu CS, Lee TH et al. Preeclampsia-eclampsia and the risk of stroke among peripartum in Taiwan // Stroke. 2009 Apr;40(4):1162-8

[196]The European Genetics Foundation; I nt Angiol. 2005 Mar;24(1):1-26.

[197]Tincani A, Andreoli L, Casu C et al. Antiphospholipid antibody profile: implications for the evaluation and management of patients // Lupus. 2010

154

Apr;19(4):432-5.

[198]Turiel M, Sarzi-Puttini P, Peretti R et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study // Stroke. 2005 Jul;36(7):1490-4.

[199]Ubbink JB, Becker PJ, Vermaak WJ, Delport R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine // Clin Chem. 1995 Jul;41(7):1033-7.

[200]Unal S, Gumruk F, Aytac S et al. Interleukin-6 (IL-6), tumor necrosis factoralpha (TNF-alpha) levels and IL-6, TNF-polymorphisms in children with thrombosis// J Pediatr Hematol Oncol. 2008 Jan;30(1):26-31.

[201]Van der Molen EF, Verbruggen B, Novakova I, et al. Hyperhomocysteinenia and other thrombotic risk factors in women with placental vasculopathy // Br J Obstet Gynaecol. 2000;107: 785-791.

[202]Villar J, Abalos E, Nardin JM, Merialdi M, Carroli G. Strategies to prevent

and treat

preeclampsia: evidence from randomized controlled trials. Semin

Nephrol 2004; 24(6): 607-15

[203]Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine pregnancy complications and adverse pregnancy outcomes: the Hordaland Homocysteine study // Am J Clin Nutr. 2000;7: 962-968.

[204]von Dadelszen P, Magee LA, Krajden M, Alasaly K, Popovska V, Devarakonda RM, et al. Levels of antibodies against CMV and C. pneumonia are increase in early onset preeclampsia. BJOG 2003; 110:725-30

[205]Von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclamosia. Hypertens Preg 2003; 22:143-148

[206]Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and deceptions // Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):375-89.

155

[207]Walker J. Pre-eclampsia. Lancet 2000: 356(9237):1260-1265.

[208]Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio // Am J Obstet Gynecol. 1998;179: 1565-1567.

[209]Williams MA, Farrand A, Mittendorf R, Sorensen TK, Zingheim RW, O`Reilly GC. Maternal second trimester serum tumor necrosis factor-α-solub receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol 1999; 149:323-329

[210]Wilton A, De Greef A, Shennan A. Rapid assessment of blood pressure in the obstetric day unit using Microlife MaM technology. Hypertens Pregnancy 2007; 26(1): 31-7

[211]Yao T., Yao H., Wang H: Diagnosis and treatment of nephritic syndrome during pregnancy. Chin Med J (Engl) 109: 471, 1996

[212]Yeo L., Ananth CV, Vintzeleos AM. Placental abruption // Gynecology and obstetrics. Vol.2 Hagerstown. Lippricott, Williams & Wilkins, 2003

[213]Yoshimura T, Ito M, Nakamura T, Okamura H. The influence of labor on thrombotic and fibrinolytic systems // Eur J Obstet Gynecol Reprod Biol. 1992 May 13;44(3):195-9.

[214]Younis JS, Samuellof A. Gestational vascular complications // Ballieres Best Pract Res Clin Haematol. 2003;16: 135-151.

[215]Zoller B., Garcia DF, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999; 84:59-70

156